Literature DB >> 27799550

Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.

Grinu Mathew1,2, Abdul Hannan1,2, Kristina Hertzler-Schaefer3, Fen Wang4, Gen-Sheng Feng5,6, Jian Zhong7, Jean J Zhao8,9, Julian Downward10, Xin Zhang11,2.   

Abstract

Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified an autocrine FGF signaling induced by loss of Pten in keratinocytes. In this study, we demonstrate that skin hyperplasia requires FGF receptor adaptor protein Frs2α and tyrosine phosphatase Shp2, two upstream regulators of Ras signaling. Although the PI3-kinase regulatory subunits p85α and p85β are dispensable, the PI3-kinase catalytic subunit p110α requires interaction with Ras to promote hyperplasia in Pten-deficient skin, thus demonstrating an important cross-talk between Ras and PI3K pathways. Furthermore, genetic and pharmacological inhibition of Ras-MAPK pathway impeded epidermal hyperplasia in Pten animals. These results reveal a positive feedback loop connecting Pten and Ras pathways and suggest that FGF-activated Ras-MAPK pathway is an effective therapeutic target for preventing skin tumor induced by aberrant Pten signaling.

Entities:  

Keywords:  Erk; FGF; Pten; Ras; skin

Mesh:

Substances:

Year:  2016        PMID: 27799550      PMCID: PMC5135310          DOI: 10.1073/pnas.1604450113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene.

Authors:  Ralf Lesche; Matthias Groszer; Jing Gao; Ying Wang; Albee Messing; Hong Sun; Xin Liu; Hong Wu
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

2.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

3.  Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase.

Authors:  Kohjiro Ueki; Claudine M Yballe; Saskia M Brachmann; David Vicent; John M Watt; C Ronald Kahn; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 4.  Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

Authors:  Edward P Carter; Abbie E Fearon; Richard P Grose
Journal:  Trends Cell Biol       Date:  2014-11-29       Impact factor: 20.808

5.  PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways.

Authors:  Denggao Yao; Claire L Alexander; Jean A Quinn; Michael J Porter; Hong Wu; David A Greenhalgh
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis.

Authors:  Charbel Darido; Smitha R Georgy; Tomasz Wilanowski; Sebastian Dworkin; Alana Auden; Quan Zhao; Gerhard Rank; Seema Srivastava; Moira J Finlay; Anthony T Papenfuss; Pier Paolo Pandolfi; Richard B Pearson; Stephen M Jane
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

7.  Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.

Authors:  Qi Wang; Thanh Von; Roderick Bronson; Minzi Ruan; Wenxia Mu; Alan Huang; Sauveur-Michel Maira; Jean J Zhao
Journal:  Genes Dev       Date:  2013-07-15       Impact factor: 11.361

8.  Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation.

Authors:  Akira Suzuki; Satoshi Itami; Minako Ohishi; Koichi Hamada; Tae Inoue; Nobuyasu Komazawa; Haruki Senoo; Takehiko Sasaki; Junji Takeda; Motomu Manabe; Tak Wah Mak; Toru Nakano
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin.

Authors:  Cristiane H Squarize; Rogerio M Castilho; J Silvio Gutkind
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice.

Authors:  L Guo; Q C Yu; E Fuchs
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  6 in total

Review 1.  The role of microRNAs in diseases and related signaling pathways.

Authors:  Atena Vaghf; Behzad Khansarinejad; Ehsanollah Ghaznavi-Rad; Mahdieh Mondanizadeh
Journal:  Mol Biol Rep       Date:  2021-10-31       Impact factor: 2.742

2.  Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling.

Authors:  Qian Wang; Chenqi Tao; Abdul Hannan; Sungtae Yoon; Xuanyu Min; John Peregrin; Xiuxia Qu; Hongge Li; Honglian Yu; Jean Zhao; Xin Zhang
Journal:  Sci Adv       Date:  2021-06-30       Impact factor: 14.136

Review 3.  Deciphering role of FGFR signalling pathway in pancreatic cancer.

Authors:  Xiaodiao Kang; Zeng Lin; Minhui Xu; Jun Pan; Zhi-Wei Wang
Journal:  Cell Prolif       Date:  2019-04-03       Impact factor: 6.831

Review 4.  Fibroblast Growth Factor Receptor Signaling in Skin Cancers.

Authors:  Malgorzata Czyz
Journal:  Cells       Date:  2019-06-04       Impact factor: 6.600

5.  The Hippo pathway integrates PI3K-Akt signals with mechanical and polarity cues to control tissue growth.

Authors:  Nerea Borreguero-Muñoz; Georgina C Fletcher; Mario Aguilar-Aragon; Ahmed Elbediwy; Zoé I Vincent-Mistiaen; Barry J Thompson
Journal:  PLoS Biol       Date:  2019-10-15       Impact factor: 8.029

Review 6.  Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.

Authors:  Chiara Francavilla; Ciara S O'Brien
Journal:  Open Biol       Date:  2022-02-23       Impact factor: 6.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.